{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:13Z","timestamp":1792786093758,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Viatris","id":[{"id":"https:\/\/ror.org\/01g1gvr46","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MR-107A-02 is a novel, oral meloxicam formulation designed to enhance dissolution and absorption for rapid analgesia in acute pain. It demonstrates a favorable pharmacokinetic profile, with a higher Cmax and shorter Tmax than Mobic\u00ae (meloxicam tablets), while maintaining similar overall extent of exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study assessed the efficacy and safety of MR-107A-02 at doses of 1.25, 5, and 15\u2009mg twice daily (BID) following third molar extraction. The primary endpoint was SPID0\u201324, analyzed in the mITT population using W6LOCF to account for rescue medication use. Pain intensity and categorical ratings were evaluated using standardized pain scales. Onset of perceptible and meaningful pain relief were measured using the double-stopwatch technique. Effect sizes and associated standard errors, p-values, and 95% CIs were estimated using an Emax model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 110 participants, MR-107A-02 demonstrated positive dose-dependent analgesia, with mean SPID0-24 Emax values of 70.7 (1.25\u2009mg), 86.7 (5\u2009mg), and 94.8 (15\u2009mg), versus 52.0 for placebo. Significant improvement in SPID0-24 occurred at 5\u2009mg and 15\u2009mg versus placebo (p\u2009&amp;lt;\u2009.001). The 15\u2009mg dose achieved perceptible and meaningful pain relief within 0.6 and 1.5\u2009hours, respectively, and had the lowest rescue medication use (29.6%) compared to 42.9%, 57.1%, and 74.1% in the 1.25\u2009mg, 5\u2009mg, and placebo. No severe TEAEs, SAEs, or discontinuations were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MR-107A-02 was generally well tolerated and demonstrated dose-dependent efficacy, with the 15\u2009mg BID dose providing rapid analgesia and a reduction in rescue medication use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinicaltrial.gov identifier<\/jats:title>\n                    <jats:p>NCT05317312 https:\/\/clinicaltrials.gov\/study\/NCT05317312<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pm\/pnag095","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:42:36Z","timestamp":1784893356000},"source":"Crossref","is-referenced-by-count":0,"title":["A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain"],"prefix":"10.1093","author":[{"given":"Todd Mitchell","family":"Bertoch","sequence":"first","affiliation":[{"name":"CenExel JBR , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Grisham","sequence":"additional","affiliation":[{"name":"CenExel JBR , Salt Lake City, UT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1918-7447","authenticated-orcid":false,"given":"Susanne","family":"Vogt","sequence":"additional","affiliation":[{"name":"Viatris , Bad Homburg, Hessen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Haughie","sequence":"additional","affiliation":[{"name":"Viatris\/Mylan Pharma, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ocasio","sequence":"additional","affiliation":[{"name":"Viatris Inc ., Canonsburg, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P","family":"Smith","sequence":"additional","affiliation":[{"name":"Viatris , Morgantown, WV,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"2026091617564420800_pnag095-B1","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S0140-6736(06)68700-X","article-title":"Persistent postsurgical pain: risk factors and prevention","volume":"367","author":"Kehlet","year":"2006","journal-title":"Lancet"},{"key":"2026091617564420800_pnag095-B2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/OGX.0000000000000677","article-title":"The opioid epidemic in the United States\u2014overview, origins, and potential solutions","volume":"74","author":"Jones","year":"2019","journal-title":"Obstet Gynecol Surv"},{"key":"2026091617564420800_pnag095-B3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths\u2014United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026091617564420800_pnag095-B4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1517\/14656566.6.12.2117","article-title":"Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety","volume":"6","author":"Gates","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"2026091617564420800_pnag095-B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0049-0172(97)80049-2","article-title":"Meloxicam: Selective COX-2 inhibition in clinical practice","volume":"26","author":"Furst","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"2026091617564420800_pnag095-B6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00044011-200222120-00001","article-title":"Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug: a review","volume":"22","author":"Del Tacca","year":"2002","journal-title":"Clin Drug Investig"},{"key":"2026091617564420800_pnag095-B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/rheumatology\/35.suppl_1.13","article-title":"A review of the clinical pharmacokinetics of meloxicam","volume":"35 Suppl 1","author":"T\u00fcrck","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2026091617564420800_pnag095-B8","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.5435\/JAAOSGlobal-D-22-00032","article-title":"Meloxicam versus Celecoxib for postoperative analgesia after total knee arthroplasty: safety, efficacy and cost","volume":"6","author":"Haffar","year":"2022","journal-title":"JAAOS Global Res Rev"},{"key":"2026091617564420800_pnag095-B9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.4103\/joacp.JOACP_133_18","article-title":"Meloxicam in the management of post-operative pain: Narrative review","volume":"34","author":"Bekker","year":"2018","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"2026091617564420800_pnag095-B10","author":"FDA","year":"2026"},{"key":"2026091617564420800_pnag095-B11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/JPR.S149879","article-title":"Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy","volume":"11","author":"Gottlieb","year":"2018","journal-title":"J Pain Res"},{"key":"2026091617564420800_pnag095-B12","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1080\/17425247.2025.2561710","article-title":"Comparison of the pharmacokinetics of MR-107A-02, a novel fast-absorbing formulation of meloxicam, versus standard meloxicam reference: a phase I study","volume":"22","author":"Hummel","year":"2025","journal-title":"Expert Opin Drug Deliv"},{"key":"2026091617564420800_pnag095-B13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.pain.2013.09.002","article-title":"A comparison of the clinical and experimental characteristics of four acute surgical pain models: dental extraction, bunionectomy, joint replacement, and soft tissue surgery","volume":"155","author":"Singla","year":"2014","journal-title":"Pain."},{"key":"2026091617564420800_pnag095-B14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/jcph.1058","article-title":"A randomized double-blind controlled trial of intravenous meloxicam in the treatment of pain following dental impaction surgery","volume":"58","author":"Christensen","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2026091617564420800_pnag095-B15","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/AJP.0000000000000609","article-title":"Efficacy and safety of intravenous meloxicam in patients with moderate-to-severe pain following bunionectomy: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Pollak","year":"2018","journal-title":"Clin J Pain"},{"key":"2026091617564420800_pnag095-B16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.0306-5251.2001.01533.x","article-title":"Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use","volume":"53","author":"Blain","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"2026091617564420800_pnag095-B17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.clinthera.2005.04.010","article-title":"Analgesic efficacy and tolerability of oxycodone 5 mg\/ibuprofen400 mg compared with those of oxycodone 5 mg\/acetaminophen 325 mg and hydrocodone 7.5 mg\/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model","volume":"27","author":"Litkowski","year":"2005","journal-title":"Clin Ther"},{"key":"2026091617564420800_pnag095-B18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/j.pain.0000000000000375","article-title":"Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations","volume":"157","author":"Cooper","year":"2016","journal-title":"Pain"},{"key":"2026091617564420800_pnag095-B19","author":"Association AD"},{"key":"2026091617564420800_pnag095-B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.adaj.2023.10.009","article-title":"Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in adolescents, adults, and older adults: a report from the American Dental Association Science and Research Institute, the University of Pittsburgh, and the University of Pennsylvania","volume":"155","author":"Carrasco-Labra","year":"2024","journal-title":"J Am Dent Assoc"},{"key":"2026091617564420800_pnag095-B21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ijom.2026.03.020","article-title":"Management of pain with oral analgesia after extraction of lower third molars: a network meta-analysis of randomized controlled trials","volume":"55","author":"Magesty","year":"2026","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2026091617564420800_pnag095-B22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.adaj.2024.10.014","article-title":"Nonopioid vs opioid analgesics after impacted third-molar extractions: The Opioid Analgesic Reduction Study randomized clinical trial","volume":"156","author":"Feldman","year":"2025","journal-title":"J Am Dent Assoc"},{"key":"2026091617564420800_pnag095-B23","author":"Association AD","year":"2026"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnag095\/70097522\/pnag095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnag095\/70097522\/pnag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:56:49Z","timestamp":1789595809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article\/doi\/10.1093\/pm\/pnag095\/8742046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1093\/pm\/pnag095","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"article-number":"pnag095"}}